abstract |
A trispecific inhibitor for use in the treatment of cancer comprises a first targeting domain having a binding specificity conferred by a VEGF binding antagonist; a second targeting domain having a binding specificity conferred by an immune checkpoint modulator binding antagonist; and a third targeting domain having binding specificity conferred by a Tie2 tyrosine kinase receptor binding antagonist. The targeting domain may comprise one or more antibody variable regions, peptide inhibitors, dominant negative proteins, small molecule drugs, or combinations thereof. |